Satsuma Pharmaceuticals, Inc. Banner Image

Satsuma Pharmaceuticals, Inc. has reached its limit for free report views

Work for Satsuma Pharmaceuticals, Inc.? Upgrade Your Profile and unlock all your annual reports.

Satsuma Pharmaceuticals, Inc.

  • Ticker STSA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Satsuma Pharmaceuticals, Inc. Logo Image
  • 11-50 Employees
  • Based in South San Francisco, California
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. In developingMore STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, non-injectable DHE product that can be rapidly self-administered in a matter of seconds.
Satsuma Pharmaceuticals, Inc.

Most Recent Annual Report

MOST RECENT 2020 Form 10K

Report Locked. Satsuma Pharmaceuticals, Inc. has reached its limit for free report views.

Older/Archived Annual Reports